TNFRSF8 positive
TNFRSF8 positive
|
Cutaneous T-cell Lymphoma
Cutaneous T-cell Lymphoma
|
|
No biomarker
No biomarker
|
Cutaneous T-cell Lymphoma
Cutaneous T-cell Lymphoma
|
|
No biomarker
No biomarker
|
Cutaneous T-cell Lymphoma
Cutaneous T-cell Lymphoma
|
|
IL2RA expression
IL2RA expression
|
Cutaneous T-cell Lymphoma
Cutaneous T-cell Lymphoma
|
|
No biomarker
No biomarker
|
Cutaneous T-cell Lymphoma
Cutaneous T-cell Lymphoma
|
|
No biomarker
No biomarker
|
Cutaneous T-cell Lymphoma
Cutaneous T-cell Lymphoma
|
RP6530
Sensitive: B - Late Trials
|
TNFRSF8 expression
TNFRSF8 expression
|
Cutaneous T-cell Lymphoma
Cutaneous T-cell Lymphoma
|
brentuximab vedotin
Sensitive: C1 - Off-label
|
PD-L1 underexpression
PD-L1 underexpression
|
Cutaneous T-cell Lymphoma
Cutaneous T-cell Lymphoma
|
durvalumab + lenalidomide
Sensitive: C3 – Early Trials
|
RPS6 underexpression
RPS6 underexpression
|
Cutaneous T-cell Lymphoma
Cutaneous T-cell Lymphoma
|
ruxolitinib
Sensitive: C3 – Early Trials
|
ICOS underexpression
ICOS underexpression
|
Cutaneous T-cell Lymphoma
Cutaneous T-cell Lymphoma
|
durvalumab
Sensitive: C3 – Early Trials
|
PD-1 overexpression
PD-1 overexpression
|
Cutaneous T-cell Lymphoma
Cutaneous T-cell Lymphoma
|
pembrolizumab
Sensitive: C3 – Early Trials
|
